Amit Pande

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Milind Javle, Sameek Roychowdhury, Robin Kate Kelley et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 398 citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +11

Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial

Shalini Makawita, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al. · Future Oncology · 2020 · 87 citations · Full text

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.

Milind Javle, Sameek Roychowdhury, Robin Kate Kelley et al. · Journal of Clinical Oncology · 2021 · 86 citations

Fgfr Fusions/rearrangements, Pathology, Phase Ii Study +18

Expression of CD71 by flow cytometry in acute leukemias: More often seen in acute myeloid leukemia

Pranav Dorwal, Amit Pande, Dharmendra Jain et al. · Indian Journal of Pathology and Microbiology · 2016 · 14 citations · Full text

Effects of different sensitization events on HLA alloimmunization in renal transplant cases; a retrospective observation in 1066 cases

Prashant Pandey, Amit Pande, Saikat Mandal et al. · Transplant Immunology · 2022 · 14 citations

Transplant Rejection, Urology, Transplantation +15